Peter Lockwood

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. ncbi request reprint The use of clinical trial simulation to support dose selection: application to development of a new treatment for chronic neuropathic pain
    Peter A Lockwood
    Clinical Pharmacokinetics and Pharmacodynamics, Pfizer Global Research and Development, Ann Arbor, MI, USA
    Pharm Res 20:1752-9. 2003
  2. ncbi request reprint Application of clinical trial simulation to compare proof-of-concept study designs for drugs with a slow onset of effect; an example in Alzheimer's disease
    Peter Lockwood
    Pfizer Global Research and Development, Ann Arbor, Michigan, USA
    Pharm Res 23:2050-9. 2006
  3. ncbi request reprint How modeling and simulation have enhanced decision making in new drug development
    Raymond Miller
    Pfizer Global Research and Development, Pfizer Inc, Ann Arbor, MI 48105, USA
    J Pharmacokinet Pharmacodyn 32:185-97. 2005

Detail Information

Publications3

  1. ncbi request reprint The use of clinical trial simulation to support dose selection: application to development of a new treatment for chronic neuropathic pain
    Peter A Lockwood
    Clinical Pharmacokinetics and Pharmacodynamics, Pfizer Global Research and Development, Ann Arbor, MI, USA
    Pharm Res 20:1752-9. 2003
    ..The likelihood of demonstrating at least a one-point change for each available dose strength was also calculated...
  2. ncbi request reprint Application of clinical trial simulation to compare proof-of-concept study designs for drugs with a slow onset of effect; an example in Alzheimer's disease
    Peter Lockwood
    Pfizer Global Research and Development, Ann Arbor, Michigan, USA
    Pharm Res 23:2050-9. 2006
    ..e., Ho: Drug Effect = 0). We evaluated if a crossover design would allow smaller and shorter duration trials...
  3. ncbi request reprint How modeling and simulation have enhanced decision making in new drug development
    Raymond Miller
    Pfizer Global Research and Development, Pfizer Inc, Ann Arbor, MI 48105, USA
    J Pharmacokinet Pharmacodyn 32:185-97. 2005
    ....